Retatrutide is the investigational weekly injection that keeps showing up in weight-loss headlines, and the numbers are striking: average losses above 20% of body weight in several phase 3 trials. It is also not approved anywhere yet. This post explains what retatrutide is, what the TRIUMPH trials have reported so far, the side effects that stand out, and why the “retatrutide” vials sold online are a different matter entirely.
What is retatrutide?
Retatrutide is a once-weekly peptide developed by Eli Lilly that activates three receptors: GLP-1 and GIP, the two targeted by tirzepatide, plus the glucagon receptor. That is why it is called a “triple agonist.” The glucagon piece is thought to add an energy-expenditure and liver-fat effect on top of reduced appetite, although the trials were not built to separate which receptor does what. For context on the two drugs it builds on, see our comparison of tirzepatide and semaglutide in head-to-head trials.
TRIUMPH-4: obesity with knee osteoarthritis
The first phase 3 readout came in December 2025. In TRIUMPH-4, adults with obesity or overweight and knee osteoarthritis were followed for 68 weeks. According to Lilly’s announcement, the 12 mg dose produced an average weight reduction of 28.7% on the efficacy estimand, versus 2.1% on placebo, with 26.4% at 9 mg. A more conservative “treatment-regimen” analysis, which counts people regardless of whether they stayed on drug, gave smaller figures: about 23.7% at 12 mg and 20% at 9 mg versus 4.6% on placebo. Both numbers are real; they answer slightly different questions, so be careful when comparing headlines.

TRIUMPH-2 and TRIUMPH-3
In July 2026, Lilly reported two more phase 3 trials, summarized by HCPLive. TRIUMPH-2 enrolled people with obesity and type 2 diabetes. Average weight loss was about 12.7%, 19.1% and 20.8% at 4 mg, 9 mg and 12 mg, with A1C falling by as much as 1.6% on average. TRIUMPH-3 enrolled people with severe obesity and established cardiovascular disease. At 80 weeks, the 12 mg dose produced a 22.6% reduction versus 3.2% on placebo. People with diabetes usually lose less weight on these drugs, which fits the lower TRIUMPH-2 numbers.
Lilly has said it plans to submit retatrutide for U.S. approval in the first quarter of 2027, once its manufacturing data package is complete. Until the FDA acts, it is an investigational drug.
Side effects and safety signals
As with other drugs in this class, the most common side effects are gastrointestinal: nausea, diarrhea, constipation, vomiting and reduced appetite. Discontinuation because of adverse events in TRIUMPH-2 ranged from about 3.8% to 11.6% across doses, compared with 4.9% on placebo. In TRIUMPH-3, it was 9.8% at 9 mg and 13.5% at 12 mg versus 4.8% on placebo.
One signal is newer and worth knowing about: dysesthesia, an abnormal skin sensation such as tingling or sensitivity to touch. In TRIUMPH-4 it was reported by 8.8% of people on 9 mg and 20.9% on 12 mg, compared with 0.7% on placebo. Lilly describes these events as generally mild and rarely leading to discontinuation, and notes that rates tracked with baseline BMI. It is still a side effect that previous drugs in the class are not known for, and long-term follow-up will matter.
On heart outcomes, fewer cardiovascular events were seen with retatrutide than placebo in some trials, but the studies were not designed to prove a cardiovascular benefit. In TRIUMPH-2 the hazard ratio for major adverse cardiovascular events was 1.12, with a confidence interval wide enough to include both benefit and harm. That is an unanswered question, not a finding.
How to read these results
- These are company toplines. Much of the detail came from press releases. Peer-reviewed publication, as with the TRIUMPH-4 knee osteoarthritis paper, adds scrutiny that a press release cannot.
- Estimands matter. “Efficacy” numbers assume people stayed on treatment; “treatment-regimen” numbers do not. Neither is wrong, but only like-for-like comparisons are fair.
- Different trials, different people. Obesity with diabetes, with heart disease and with knee osteoarthritis are not the same populations. Do not line up numbers across trials as if they were a head-to-head.
- Higher doses cost more tolerability. Larger effects came with higher discontinuation and more dysesthesia in the top dose groups.
- Weight loss is not the only endpoint. What people ultimately want to know is whether it improves health outcomes over years. That is still being established.
How does it compare with tirzepatide and semaglutide?
It is tempting to line up retatrutide’s 20%-plus figures next to tirzepatide’s roughly 20% in SURMOUNT-5 and semaglutide’s roughly 14%, and declare a winner. That is not a valid comparison. The trials enrolled different people, ran for different lengths, used different analysis methods, and have not pitted the drugs against each other. What the evidence supports is narrower: in its own placebo-controlled trials, retatrutide produced large average weight loss, in the same general range as the best results seen with tirzepatide and in some analyses higher. A direct head-to-head trial would be needed to say more.
Who might benefit, and who was studied
The TRIUMPH program deliberately targets groups with extra health burdens: people with type 2 diabetes, cardiovascular disease, knee osteoarthritis and, in planned filings, obstructive sleep apnea. Those are populations where weight loss may translate into symptom relief or better markers of health, and they are also groups with a lot at stake if a side effect appears. Trial participants are screened and monitored, and people with certain conditions are excluded. Results for older adults, people with kidney or liver disease, or those taking many other medicines may differ.
What to watch for next
Three things will shape how this drug is judged. First, full peer-reviewed papers for the July 2026 trials, which will show the details behind the press-release figures. Second, longer follow-up on dysesthesia and other nerve-related symptoms, including whether they fade over time. Third, whether retatrutide shows lower rates of cardiovascular events or other hard outcomes in studies designed to test that. Regulatory review, expected to begin with a first-quarter 2027 submission, will add an independent look at the data.
What about the retatrutide sold online?
Because retatrutide is not approved, any product sold today is either part of a clinical trial or an unregulated “research chemical.” Those vials are not made under the quality controls used for the trial drug, so the identity, purity and dose can differ from the label, and nothing about the TRIUMPH results tells you what a given vial will do. If a seller uses Lilly’s trial numbers to market a product, that is a mismatch worth questioning. Anyone interested in the drug should talk to a clinician and look at trial enrollment through the official registry.
Bottom line
Retatrutide is one of the most effective weight-loss drugs studied so far, based on the company-reported phase 3 results, and it adds a new side effect to watch for. It is also unapproved, its detailed data are still emerging, and the long-term safety picture is not complete. Expect more detail when the full papers appear and the FDA reviews it. Want to compare notes with other readers? The forum is open.
This article is for educational purposes only and is not medical advice. Figures come from company announcements and news coverage and may differ from the final published papers. Retatrutide is not approved by the FDA. Talk to a qualified clinician before using any prescription or research compound.



Leave a Reply